Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

GSK announced that it has notified the European Medicines Agency of its decision to withdraw the Marketing Authorisation Application in the EU for mepolizumab for the treatment of hypereosinophilic syndrome.

Related Articles

Successful Treatment With Sumatriptan in a Case With Cyclic Vomiting Syndrome Combined With 18q– Syndrome
Journal of Child Neurology, 10/02/09    Relevance Score: 47%

Metabolic Syndrome Among College Students
The Journal for Nurse Practitioners, 11/19/09    Relevance Score: 46%

Common infectious agents prevalence in antiphospholipid syndrome
Lupus, 11/05/09    Relevance Score: 46%

A Prospective Investigation of Biomechanical Risk Factors for Patellofemoral Pain Syndrome: The Joint Undertaking to Monitor and Prevent ACL Injury (JUMP-ACL) Cohort
American Journal of Sports Medicine, 11/02/09    Relevance Score: 46%

Adult-onset Still’s disease, Schnitzler syndrome, and autoinflammatory syndromes in adulthood
Zeitschrift für Rheumatologie, 10/29/09    Relevance Score: 46%

Today in Regulatory Issues...keeping you current

The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09

Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09

FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address